Soluble α-Klotho: A novel serum biomarker for the activity of GH-producing pituitary adenomas

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 575-583

  Neidert, Marian Christoph ^a   Sze, Lisa ^a,b   Zwimpfer, Cornelia ^a   Sarnthein, Johannes ^a   Seifert, Burkhardt ^c   Frei, Karl ^a   Leske, Henning ^a   Rushing, Elisabeth Jane ^a   Schmid, Christoph ^a   Bernays, René Ludwig ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Division of Endocrinology and Diabetes   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; ALPHA KLOTHO GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; TRANSSPHENOIDAL SURGERY;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GLUCURONIDASE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOLUBILITY; YOUNG ADULT;

EID: 84875139918     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-1045     Document Type: Article

References (41)

1. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997 390 45-51. (doi:10.1038/36285)
2. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H et al. Suppression of aging in mice by the hormone Klotho. Science 2005 309 1829-1833. (doi:10.1126/science.1112766)
3. Arking DE, Krebsova A, Macek M Sr, Macek M Jr, Arking A, Mian IS, Fried L, Hamosh A, Dey S, McIntosh I et al. Association of human aging with a functional variant of Klotho. PNAS 2002 99 856-861. (doi:10.1073/pnas.022484299)
4. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE & Econs MJ. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. Journal of Clinical Investigation 2007 117 2684-2691. (doi:10.1172/JCI31330)
5. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S & Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 444 770-774. (doi:10.1038/nature05315)
6. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW et al. Regulation of fibroblast growth factor-23 signaling by Klotho. Journal of Biological Chemistry 2006 281 6120-6123. (doi:10.1074/jbc.C500457200)
7. Kuro-o M. Klotho and aging. Biochimica et Biophysica Acta 2009 1790 1049-1058. (doi:10.1016/j.bbagen.2009.02.005)
8. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N et al. α-Klotho as a regulator of calcium homeostasis. Science 2007 316 1615-1618. (doi:10.1126/science.1135901)
9. Chen CD, Podvin S, Gillespie E, Leeman SE & Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. PNAS 2007 104 19796-19801. (doi:10.1073/pnas.0709805104)
10. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T & Nabeshima Y. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Letters 2004 565 143-147. (doi:10.1016/j.febslet.2004.03.090)
11. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Yet al. Establishment of sandwich ELISA for soluble α-Klotho measurement: agedependent change of soluble α-Klotho levels in healthy subjects. Biochemical and Biophysical Research Communications 2010 398 513-518. (doi:10.1016/j.bbrc.2010.06.110)
12. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, Guralnik JM & Ferrucci L. Plasma Klotho and mortality risk in older community-dwelling adults. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2011 66 794-800. (doi:10.1093/gerona/glr058)
13. Ohata Y, Arahori H, Namba N, Kitaoka T, Hirai H, Wada K, Nakayama M, Michigami T, Imura A, Nabeshima Y et al. Circulating levels of soluble α-Klotho are markedly elevated in human umbilical cord blood. Journal of Clinical Endocrinology and Metabolism 2011 96 E943-E947. (doi:10.1210/jc.2010- 2357)
14. Siahanidou T, Garatzioti M, Lazaropoulou C, Kourlaba G, Papassotiriou I, Kino T, Imura A, Nabeshima Y & Chrousos G. Plasma soluble α-Klotho protein levels in premature and term neonates: correlations with growth and metabolic parameters. European Journal of Endocrinology 2012 167 433-440. (doi:10.1530/EJE-12-0476)
15. Holdaway IM & Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41. (doi:10.1023/A:1009965803750)
16. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
17. Corvilain J, Abramow M & Bergans A. Some effects of human growth hormone on renal hemodynamics and on tubular phosphate transport in man. Journal of Clinical Investigation 1962 41 1230-1235. (doi:10.1172/JCI104584)
18. Lund B, Eskildsen PC, Lund B, Norman AW & Sorensen OH. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinologica 1981 96 444-450.
19. Takamoto S, Tsuchiya H, Onishi T, Morimoto S, Imanaka S, Mori S, Seino Y, Uozumi T & Kumahara Y. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. Journal of Clinical Endocrinology and Metabolism 1985 61 7-11. (doi:10.1210/jcem-61-1-7)
20. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G & Cholesterol and Recurrent Events Trial I. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005 112 2627-2633. (doi:10.1161/CIRCULATIONAHA.105.553198)
21. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clinical Journal of the American Society of Nephrology 2009 4 1136-1139. (doi:10.2215/CJN.01660309)
22. Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brandle M & Schmid C. Excessively high soluble Klotho in patients with acromegaly. Journal of Internal Medicine 2012 272 93-97.
23. Bellut D, Hlavica M, Schmid C & Bernays RL. Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly. Neurosurgical Focus 2010 29 E9. (doi:10.3171/2010.7.FOCUS10164)
24. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M & Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochemical and Biophysical Research Communications 1998 242 626-630. (doi:10.1006/bbrc.1997.8019)
25. Bloch L, Sineshchekova O, Reichenbach D, Reiss K, Saftig P, Kuro-o M & Kaether C. Klotho is a substrate for α-, α-and γ-secretase. FEBS Letters 2009 583 3221-3224. (doi:10.1016/j.febslet.2009. 09.009)
26. Saftig P & Reiss K. The "A Disintegrin and Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? European Journal of Cell Biology 2011 90 527-535. (doi:10.1016/j.ejcb.2010.11.005)
27. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
28. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D et al. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740. (doi:10.1530/eje.1.02036)
29. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J et al. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
30. Zapf J. Physiological role of the insulin-like growth factor binding proteins. European Journal of Endocrinology 1995 132 645-654. (doi:10.1530/eje.0.1320645)
31. Ranke MB & Elmlinger M. Functional role of insulin-like growth factor binding proteins. Hormone Research 1997 48 (Suppl 4) 9-15. (doi:10.1159/ 000191304)
32. Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007 10 121-128. (doi:10.1007/s11102-007-0032-z)
33. Zapf J, Morell B, Walter H, Laron Z & Froesch ER. Serum levels of insulin-like growth factor (IGF) and its carrier protein in various metabolic disorders. Acta Endocrinologica 1980 95 505-517.
34. Zapf J, Walter H & Froesch ER. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. Journal of Clinical Investigation 1981 68 1321-1330. (doi:10.1172/JCI110379)
35. Subbarayan S, Fleseriu M, Gordon M, Brzana J, Kennedy L, Faiman C, Hatipoglu B, Prayson RA, Delashaw JB, Weil RJ et al. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocrine Practice 2012 18 817-825. (doi:10.4158/EP11324.OR)
36. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C & Pfeiffer AF. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 2008 93 1254-1262. (doi:10.1210/jc.2007-2084)
37. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177. (doi:10.1056/NEJM200004203421604)
38. van der Klaauw AA, Pereira AM, van Thiel SW, Frolich M, Iranmanesh A, Veldhuis JD, Roelfsema F & Romijn JA. Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients. Clinical Endocrinology 2007 66 489-498. (doi:10.1111/j.1365-2265.2006.02757.x)
39. Bidlingmaier M & Strasburger CJ. Growth hormone assays: current methodologies and their limitations. Pituitary 2007 10 115-119. (doi:10.1007/s11102-007-0030-1)
40. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry 2011 57 555-559. (doi:10.1373/clinchem.2010.150631)
41. Neggers SJ, Biermasz NR & van der Lely AJ. What is active acromegaly and which parameters do we have? Clinical Endocrinology 2012 76 609-614. (doi:10.1111/j.1365-2265.2012.04346.x)